JMIT, the first randomized study to examine pemetrexed plus EGFR-TKI therapy as first-line treatment for advanced NSCLC patients with activating EGFR mutations, showed that the combination therapy improved PFS compared with TKI monotherapy [26]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.